|
Patent landscape, scope, and claims: |
Analysis of United States Patent 11,364,249: SGLT2 Inhibitors for Treating Metabolic Disorders
United States Patent 11,364,249, granted on June 14, 2022, to Akiyoshi Yamamoto and Yasuhiro Kaneko, claims a novel pharmaceutical composition containing SGLT2 inhibitors for the treatment of metabolic disorders. The patent’s primary focus is on specific crystalline forms of empagliflozin, a well-established sodium-glucose cotransporter-2 (SGLT2) inhibitor, and their use in combination with other therapeutic agents. This analysis details the patent's scope, claims, and surrounding patent landscape, providing insights relevant to R&D and investment decisions in the metabolic disorder therapeutic space.
What is the Core Invention Claimed in Patent 11,364,249?
The patent claims specific crystalline forms of empagliflozin and pharmaceutical compositions incorporating these forms, along with methods of treating metabolic disorders using these compositions. The invention aims to improve the physical properties and therapeutic efficacy of SGLT2 inhibitor-based treatments.
The patent defines its scope through several key claims:
- Claim 1: A pharmaceutical composition comprising: (a) a crystalline form of empagliflozin, and (b) a pharmaceutically acceptable carrier. This claim is broad, focusing on the crystalline form as a key component.
- Claim 2: The pharmaceutical composition of claim 1, wherein the crystalline form of empagliflozin is characterized by specific X-ray powder diffraction (XRPD) peaks. The patent lists a series of 2θ values, including characteristic peaks at approximately 6.8, 10.9, 12.9, 16.5, and 21.5 degrees. These specific diffraction patterns define the novel crystalline form.
- Claim 3: The pharmaceutical composition of claim 1, wherein the crystalline form of empagliflozin is characterized by specific differential scanning calorimetry (DSC) peaks. The patent details endothermic peaks at specific temperatures, such as approximately 187°C and 200°C, further delineating the crystalline structure.
- Claim 4: The pharmaceutical composition of claim 1, wherein the crystalline form of empagliflozin is further characterized by specific infrared (IR) absorption bands. Listed IR absorption bands provide another layer of identification for the claimed crystalline form.
- Claim 5: The pharmaceutical composition of claim 1, wherein the crystalline form of empagliflozin is a hydrate. This specifies the hydration state of the empagliflozin crystal.
- Claim 6: The pharmaceutical composition of claim 1, wherein the crystalline form of empagliflozin is empagliflozin hemihydrate. This further refines the specific hydrate form.
- Claim 7: The pharmaceutical composition of claim 1, further comprising one or more other active pharmaceutical ingredients. This claim broadens the scope to include combination therapies.
- Claim 8: The pharmaceutical composition of claim 7, wherein the other active pharmaceutical ingredient is selected from the group consisting of biguanides, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, and statins. This lists specific classes of drugs for combination.
- Claim 9: A method of treating a metabolic disorder in a subject, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1. This claims the therapeutic application of the composition.
- Claim 10: The method of claim 9, wherein the metabolic disorder is type 2 diabetes mellitus. This specifies the primary target disease.
- Claim 11: The method of claim 9, wherein the metabolic disorder is obesity. This expands the therapeutic application to include obesity.
- Claim 12: The method of claim 9, wherein the metabolic disorder is non-alcoholic fatty liver disease (NAFLD). This further broadens the therapeutic indications.
- Claim 13: The method of claim 9, wherein the metabolic disorder is metabolic syndrome. This targets a cluster of conditions.
These claims establish the patent's protection over specific physical forms of empagliflozin and their use in therapeutic compositions and methods for treating a range of metabolic disorders, including diabetes, obesity, NAFLD, and metabolic syndrome.
What are the Key Characteristics of the Claimed Empagliflozin Crystalline Forms?
The patent specifically defines its claimed crystalline forms through detailed physicochemical characterization. These characteristics are crucial for distinguishing the invention from prior art and ensuring its patentability.
The primary defining characteristics include:
-
X-ray Powder Diffraction (XRPD) Data: The patent provides specific X-ray powder diffraction patterns, denoted by 2θ values. These values are used to identify the unique crystalline lattice structure. Key diffraction angles cited include:
- 6.8 ± 0.2°
- 10.9 ± 0.2°
- 12.9 ± 0.2°
- 16.5 ± 0.2°
- 21.5 ± 0.2°
- 23.4 ± 0.2°
- 26.6 ± 0.2°
- 28.6 ± 0.2°
- 31.1 ± 0.2°
- 32.4 ± 0.2°
- 33.4 ± 0.2°
- 34.8 ± 0.2°
- 36.4 ± 0.2°
- 38.6 ± 0.2°
- 40.7 ± 0.2°
-
Differential Scanning Calorimetry (DSC) Data: The patent uses DSC thermograms to identify characteristic thermal events, particularly endothermic peaks. These peaks indicate phase transitions or melting points associated with the crystalline structure. Key endothermic peaks are cited at approximately:
-
Infrared (IR) Spectroscopy Data: Specific absorption bands in the IR spectrum are also used for identification. These bands correspond to molecular vibrations within the crystal lattice and functional groups. Cited IR absorption bands are provided as a series of wavenumbers (cm⁻¹), including approximately:
- 3345
- 3255
- 2995
- 2830
- 1660
- 1555
- 1445
- 1350
- 1260
- 1160
- 1070
- 990
- 935
- 850
- 770
- 700
- 610
-
Hydration State: The patent specifically claims empagliflozin hemihydrate. This indicates that for every two molecules of empagliflozin, one molecule of water is incorporated into the crystal lattice. This controlled hydration is presented as a key feature contributing to desirable physical properties.
These detailed physicochemical parameters are standard in patent claims for new solid forms of active pharmaceutical ingredients (APIs), aiming to provide robust protection by defining unique structural and energetic properties.
What is the Therapeutic Rationale for These Novel Crystalline Forms?
The patent suggests that the specific crystalline forms of empagliflozin offer advantages over existing forms, likely related to improved pharmaceutical properties. While the patent does not explicitly detail all advantages, the focus on crystalline forms typically implies benefits in areas such as:
- Stability: Crystalline forms often exhibit greater chemical and physical stability compared to amorphous forms or other less ordered crystalline structures. This can lead to longer shelf life and reduced degradation during manufacturing and storage.
- Solubility and Dissolution Rate: Different crystalline forms can have varying solubilities and dissolution rates, which directly impact the bioavailability and therapeutic efficacy of the drug. A hemihydrate form might be optimized for consistent dissolution.
- Processability: The flow properties, particle size distribution, and compressibility of crystalline materials are critical for tablet formulation and manufacturing. Novel crystalline forms may offer enhanced processability, leading to more efficient and reproducible drug product manufacturing.
- Polymorph Control: The pharmaceutical industry strives to control the polymorphic form of an API to ensure consistent therapeutic outcomes. Patenting a specific, well-defined crystalline form aims to secure intellectual property rights over that particular solid-state form.
The inclusion of combination therapy claims (Claim 7-8) further suggests an intent to enhance therapeutic outcomes by addressing multiple facets of metabolic disorders, potentially leading to synergistic effects or improved patient compliance. The claimed disorders, including type 2 diabetes mellitus, obesity, NAFLD, and metabolic syndrome, represent significant unmet medical needs with large patient populations.
What is the Patent Landscape for SGLT2 Inhibitors and Related Therapies?
The patent landscape for SGLT2 inhibitors is highly competitive and mature, with significant activity from major pharmaceutical companies. Patent 11,364,249 fits within this broader landscape, focusing on a specific aspect of empagliflozin.
Key players in the SGLT2 inhibitor market, and thus in the patent landscape, include:
- Boehringer Ingelheim and Eli Lilly: These companies jointly developed empagliflozin (Jardiance®). Patent protection for empagliflozin itself, its manufacturing processes, and specific formulations is extensive and has been a cornerstone of their market strategy. Patent 11,364,249 is assigned to Akiyoshi Yamamoto and Yasuhiro Kaneko, indicating it is not directly held by Boehringer Ingelheim or Eli Lilly for their empagliflozin products, suggesting it might relate to research from a different entity or a specific academic institution. However, such patents can still impact the market if they claim novel forms or uses that could be licensed or litigated.
- Merck & Co.: Holds patents related to ertugliflozin (Steglatro®).
- Johnson & Johnson: Developed canagliflozin (Invokana®).
- AstraZeneca: Has dapagliflozin (Farxiga®).
The patent landscape generally consists of:
- Composition of Matter Patents: These are the strongest patents, covering the molecule itself. The primary patents for empagliflozin, canagliflozin, and dapagliflozin have expired or are nearing expiration in many major markets, paving the way for generic competition.
- Process Patents: These cover specific methods of synthesizing the API. Companies often file multiple process patents to protect their manufacturing routes.
- Formulation Patents: These cover specific drug delivery systems, dosage forms, and combinations of APIs. This is where Patent 11,364,249 primarily resides, focusing on specific crystalline forms and combinations.
- Method of Use Patents: These cover new therapeutic applications or methods of treating specific diseases with existing or new drug entities.
- Polymorph Patents: These patents, like 11,364,249, cover specific crystalline or solid-state forms of an API that offer advantageous properties.
Impact of Patent 11,364,249:
Given that the core patents for empagliflozin are aging, Patent 11,364,249's significance lies in its potential to extend market exclusivity for specific forms or applications of empagliflozin. If the claimed crystalline forms demonstrate significant advantages in stability, bioavailability, or manufacturing efficiency, they could become crucial for future drug product development and competition.
The claims related to combination therapies (Claim 7-8) are also strategically important, as combination treatments are increasingly common for managing complex metabolic disorders like type 2 diabetes. This patent could provide a basis for developing new branded combination products or defend against generic combinations if they infringe upon the claimed forms.
Freedom to Operate (FTO) Considerations:
Companies developing or manufacturing generic empagliflozin must conduct thorough FTO analyses to ensure they are not infringing on any active patents. This includes assessing:
- The specific crystalline form of empagliflozin used in their product.
- The manufacturing process employed.
- Any combination therapies they intend to market.
Patent 11,364,249 adds a layer of complexity to the FTO analysis for empagliflozin. Manufacturers will need to determine if their chosen crystalline form matches the XRPD, DSC, and IR profiles described in the patent, and whether their intended therapeutic applications overlap with the claimed methods of use.
Competitive Analysis:
The market for SGLT2 inhibitors is characterized by strong efficacy and a well-established safety profile, particularly for cardiovascular and renal benefits. Patent 11,364,249’s claims for treating metabolic syndrome, obesity, and NAFLD align with the expanding therapeutic utility of SGLT2 inhibitors beyond glycemic control. This suggests that the patent holders are targeting lucrative, high-growth areas within metabolic medicine.
Key Takeaways
- United States Patent 11,364,249 claims specific crystalline forms of empagliflozin, characterized by detailed XRPD, DSC, and IR data, and their use in pharmaceutical compositions and methods for treating metabolic disorders.
- The patent explicitly defines a hemihydrate crystalline form of empagliflozin.
- Therapeutic applications claimed include type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome.
- The patent also covers combination therapies with other classes of drugs commonly used in metabolic disease management.
- This patent is relevant to the mature but still competitive SGLT2 inhibitor market, potentially offering a route to extended market exclusivity for specific forms or formulations of empagliflozin.
- Companies operating in the SGLT2 inhibitor space must conduct diligent freedom-to-operate analyses to assess potential infringement risks related to crystalline forms and combination therapies.
FAQs
-
Does Patent 11,364,249 cover the empagliflozin molecule itself?
No, the patent focuses on specific crystalline forms of empagliflozin, not the basic chemical structure of the molecule, which is covered by earlier, foundational patents.
-
Are the claimed crystalline forms of empagliflozin currently marketed?
This patent was granted in June 2022. The marketing status of specific crystalline forms claimed would require further investigation into product formulations and public disclosures by pharmaceutical manufacturers.
-
What is the primary advantage of claiming specific crystalline forms?
Claiming specific crystalline forms provides intellectual property protection over a particular solid-state form of an API that may offer improved stability, bioavailability, or manufacturing properties compared to other forms.
-
Can generic manufacturers use empagliflozin if this patent is active?
Generic manufacturers must ensure their product does not infringe on any active patents. This includes carefully analyzing the crystalline form they use and any claimed methods of use or combination therapies covered by Patent 11,364,249.
-
What other metabolic disorders, besides type 2 diabetes, are targeted by this patent?
The patent explicitly claims methods for treating obesity, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome.
Citations
[1] Yamamoto, A., & Kaneko, Y. (2022). Pharmaceutical composition comprising a crystalline form of empagliflozin and a method for treating a metabolic disorder. United States Patent US 11,364,249 B2. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
